4.10.2022 | University of Eastern Finland

Marginum selected by University of Eastern Finland to Stage Two

Marginum Ltd will compete as a representative of the University of Eastern Finland (UEF) at the Stage Two event on October 20–21, 2022. Stage Two is a competition for startup companies organized in Berlin, in which 48 companies from 21 different countries participate. Those who succeed in the competition will be awarded a total of 35 000 EUR in prize money and the opportunity to negotiate capital investments for a total of 2.2 million EUR.

Marginum Ltd is medical technology company developing smart tissue monitoring which enables the operating surgeon to better identify cancer cells at areas where administered fluorescent markers accumulate. Later, the device is intended to be used in other areas such as ovarian, liver and colon cancers. The device is rooted in interdisciplinary research of the University of Eastern Finland, the Department of Neurosurgery of Kuopio University Hospital and the Eastern Finland Microsurgery Center.

Samu Lehtonen, CEO & Co-Founder of Marginum, will pitch in the competition. Lehtonen studies medicine at the University of Eastern Finland. Marginum has previously won the main prize in the annual Tahko Ski Lift Pitch competition in April 2022.

Behind the Stage Two competition is a network of 45 top European universities. The University of Eastern Finland has been involved with the event for two years and also visited Berlin in October 2021 when the event was organized for the first time. The vision of the Stage Two network is to bring together the leading universities, startups of the future, industry leaders and investors across national borders.

ADDITIONAL INFORMATION

Tomi Tuovinen
Entrepreneurship and Innovation Services, University of Eastern Finland, tomi.tuovinen@uef.fi, +358 50 571 5046

Samu Lehtonen
CEO, Marginum Ltd, samu.lehtonen@marginum.com, +358 40 579 7890

The original full article in Finnish can be read at University of Eastern Finland website.

Marginum Ltd on social media:

LATEST NEWS & PRESS

17.3.2025 | Marginum News

HIVEN® multinational clinical trial launched at Oslo University Hospital

Oslo University Hospital has joined the HIVEN® multicenter trial investigating the clinical performance of the aspirate tissue monitoring method.

15.10.2024 | Marginum News

1st patient treated with Marginum technology in Tampere

To date, this is the first patient in the world treated with fluorescence-guided aspirate tissue monitoring technology utilising the Marginum HIVEN® device.

28.6.2024 | Marginum News

Marginum quality management system ISO 13485:2016 certified

The quality management system of Marginum has been assessed and certified as meeting the requirements of ISO 13485:2016 and EN ISO 13485:2016.

10.11.2023 | Marginum News

Marginum raises €1.7 million for market entry of tissue sensing technology for cancer surgery

Almaral, Nostetta Ventures, and Redstone led the investment into Finnish medical technology company Marginum, coupled with Business Finland R&D loan.

22.3.2023 | Marginum News

Marginum started clinical trials of a new technique for tumour surgery

Marginum Ltd has initiated its first-in-human clinical trials with the aspirate tissue monitor at the Kuopio University Hospital.

21.2.2023 | Tahko Ski Lift Pitch

Marginum – Next-generation technology for cancer surgery

Tahko Ski Lift Pitch winner Marginum is pioneering optic tissue monitoring with groundbreaking innovation borne from multidisciplinary UEF research.